{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:02:46Z","timestamp":1781078566711,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"DOI":"10.7759\/cureus.89949","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:35:15Z","timestamp":1755063315000},"source":"Crossref","is-referenced-by-count":1,"title":["An Observational Study to Evaluate the Effect of L-ornithine L-aspartate in Patients With Overt Hepatic Encephalopathy Receiving Lactulose and Rifaximin"],"prefix":"10.7759","author":[{"given":"Saheli","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinthaparthi","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Bhrugumalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Soanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Hepatic encephalopathy","author":"Worobetz LJ","year":"2000","unstructured":"Worobetz LJ. Hepatic encephalopathy. First Principles of Gastroenterology. Third Edition. Thomson AR, Shaffer EA (ed): University of Toronto press, Toronto, CA; 2000. 537-9."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup H","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al.. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014, 60:715-35. 10.1002\/hep.27210","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1746-6342.2006.03215.x","article-title":"Review article: the burden of hepatic encephalopathy","volume":"25","author":"Poordad FF","year":"2007","unstructured":"Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007, 25:3-9. 10.1111\/j.1746-6342.2006.03215.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04211.x","article-title":"Review article: the modern management of hepatic encephalopathy","volume":"31","author":"Bajaj JS","year":"2010","unstructured":"Bajaj JS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther. 2010, 31:537-47. 10.1111\/j.1365-2036.2009.04211.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1023\/b:mebr.0000043980.74574.eb","article-title":"Blood ammonia levels and hepatic encephalopathy","volume":"19","author":"Lockwood AH","year":"2004","unstructured":"Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis. 2004, 19:345-9. 10.1023\/b:mebr.0000043980.74574.eb","journal-title":"Metab Brain Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21533","article-title":"Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy","volume":"45","author":"Prasad S","year":"2007","unstructured":"Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007, 45:549-59. 10.1002\/hep.21533","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(02)00350-1","article-title":"Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial","volume":"38","author":"Mas A","year":"2003","unstructured":"Mas A, Rod\u00e9s J, Sunyer L, et al.. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003, 38:51-8. 10.1016\/s0168-8278(02)00350-1","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass NM","year":"2010","unstructured":"Bass NM, Mullen KD, Sanyal A, et al.. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010, 362:1071-81. 10.1056\/NEJMoa0907893","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3945\/jn.113.174375","article-title":"Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials","volume":"143","author":"Gluud LL","year":"2013","unstructured":"Gluud LL, Dam G, Borre M, et al.. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. J Nutr. 2013, 143:1263-8. 10.3945\/jn.113.174375","journal-title":"J Nutr"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250609","article-title":"Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study","volume":"25","author":"Kircheis G","year":"1997","unstructured":"Kircheis G, Nilius R, Held C, et al.. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology. 1997, 25:1351-60. 10.1002\/hep.510250609","journal-title":"Hepatology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(98)80237-7","article-title":"Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study","volume":"28","author":"Stauch S","year":"1998","unstructured":"Stauch S, Kircheis G, Adler G, et al.. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol. 1998, 28:856-64. 10.1016\/s0168-8278(98)80237-7","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-1808-1_28","article-title":"Hepatic encephalopathy","author":"Kormis KK","year":"1998","unstructured":"Kormis KK, Wu GY. Hepatic encephalopathy. Diseases of the Liver and Bile Ducts. Current Clinical Practice. Wu GY, Israel J (ed): Humana Press, Totowa, NJ; 1998. 10.1007\/978-1-4612-1808-1_28"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02030.x","article-title":"Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines","volume":"29","author":"Guerit JM","year":"2009","unstructured":"Guerit JM, Amantini A, Fischer C, et al.. Neurophysiological investigations of hepatic encephalopathy: ISHEN practice guidelines. Liver Int. 2009, 29:789-96. 10.1111\/j.1478-3231.2009.02030.x","journal-title":"Liver Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5710.633","article-title":"Method for measuring cerebral dysfunction in patients with liver disease","volume":"2","author":"Zeegen R","year":"1970","unstructured":"Zeegen R, Drinkwater JE, Dawson AM. Method for measuring cerebral dysfunction in patients with liver disease. Br Med J. 1970, 2:633-6. 10.1136\/bmj.2.5710.633","journal-title":"Br Med J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1023\/a:1021934607762","article-title":"Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy","volume":"17","author":"Kircheis G","year":"2002","unstructured":"Kircheis G, Wettstein M, Dahl Sv, H\u00e4ussinger D. Clinical efficacy of L-ornithine-L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis. 2002, 17:453-62. 10.1023\/a:1021934607762","journal-title":"Metab Brain Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1023\/a:1020613314572","article-title":"L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action","volume":"13","author":"Rose C","year":"1998","unstructured":"Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998, 13:147-57. 10.1023\/a:1020613314572","journal-title":"Metab Brain Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29410","article-title":"L-ornithine L-aspartate in bouts of overt hepatic encephalopathy","volume":"67","author":"Sidhu SS","year":"2018","unstructured":"Sidhu SS, Sharma BC, Goyal O, Kishore H, Kaur N. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2018, 67:700-10. 10.1002\/hep.29410","journal-title":"Hepatology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32255","article-title":"L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial","volume":"75","author":"Jain A","year":"2022","unstructured":"Jain A, Sharma BC, Mahajan B, et al.. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial. Hepatology. 2022, 75:1194-1203. 10.1002\/hep.32255","journal-title":"Hepatology"},{"key":"ref19","article-title":"Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study","volume":"5","author":"Poo JL","year":"2006","unstructured":"Poo JL, G\u00f3ngora J, S\u00e1nchez-Avila F, et al.. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol. 2006, 5:281-8.","journal-title":"Ann Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001137","article-title":"Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo","volume":"30","author":"Varakanahalli S","year":"2018","unstructured":"Varakanahalli S, Sharma BC, Srivastava S, Sachdeva S, Dahale AS. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. Eur J Gastroenterol Hepatol. 2018, 30:951-8. 10.1097\/MEG.0000000000001137","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.71926","article-title":"Effect of L-ornithine L-aspartate against thioacetamide-induced hepatic damage in rats","volume":"42","author":"Najmi AK","year":"2010","unstructured":"Najmi AK, Pillai KK, Pal SN, Akhtar M, Aqil M, Sharma M. Effect of L-ornithine L-aspartate against thioacetamide-induced hepatic damage in rats. Indian J Pharmacol. 2010, 42:384-7. 10.4103\/0253-7613.71926","journal-title":"Indian J Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388421-an-observational-study-to-evaluate-the-effect-of-l-ornithine-l-aspartate-in-patients-with-overt-hepatic-encephalopathy-receiving-lactulose-and-rifaximin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T05:35:16Z","timestamp":1755063316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388421-an-observational-study-to-evaluate-the-effect-of-l-ornithine-l-aspartate-in-patients-with-overt-hepatic-encephalopathy-receiving-lactulose-and-rifaximin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.89949","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}